Patents by Inventor Randall M. Goldblum

Randall M. Goldblum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8883154
    Abstract: The present invention is drawn to antibody-mediated modulation of allergy. In this regard, the present invention discloses a monoclonal antibody, antigen-binding fragment or mimic thereof directed against Group 1 pollen allergens or homologues thereof. Also disclosed herein is the mechanism by which the disclosed monoclonal antibody, antigen binding fragment or mimic thereof will improve immunotherapy of allergic reactions in an individual. It is contemplated that herein that such a monoclonal antibody, antigen binding fragment or mimic thereof may also be useful in treatment of several microbial infections.
    Type: Grant
    Filed: December 14, 2009
    Date of Patent: November 11, 2014
    Assignee: The Board of Regents of the University of Texas Systems
    Inventors: Randall M. Goldblum, Terumi Midoro-Horiuti, Bo Ning, Ruby Tiwari
  • Publication number: 20100104571
    Abstract: The present invention is drawn to antibody-mediated modulation of allergy. In this regard, the present invention discloses a monoclonal antibody, antigen-binding fragment or mimic thereof directed against Group 1 pollen allergens or homologues thereof. Also disclosed herein is the mechanism by which the disclosed monoclonal antibody, antigen binding fragment or mimic thereof will improve immunotherapy of allergic reactions in an individual. It is contemplated that herein that such a monoclonal antibody, antigen binding fragment or mimic thereof may also be useful in treatment of several microbial infections.
    Type: Application
    Filed: December 14, 2009
    Publication date: April 29, 2010
    Inventors: Randall M. Goldblum, Terumi Midoro-Horiuti, Bo Ning, Ruby Tiwari
  • Patent number: 7284986
    Abstract: A medical training manikin having a body, a model of a lung including inflatable airways communicating with the lung model, and fastener means for selectively attaching the model of a lung to the body. The model of a lung is used to demonstrate various lung functions and ailments.
    Type: Grant
    Filed: November 2, 2005
    Date of Patent: October 23, 2007
    Assignee: Legacy Products, Inc.
    Inventors: Harold Benedict Winnike, Anne Louise Meng, Susan Winterroth McConnell, Randall M. Goldblum, Nanette Eugenie Jay, Regina Burdett, Edward Gautier Brooks, Lynda Marie Williams, Katherine L. Miller
  • Patent number: 5484707
    Abstract: Methods of monitoring and detecting the early onset of organ injury incident rejection of a organ rejection in an animal are disclosed. The described methods are capable of distinguishing organ rejection injury from other organ tissue damage in the animal. Free secretory component levels in an animal biological fluid (e.g., bile, urine, blood, amniotic fluid) may be used to identify organ rejection in an animal. Multiple and single organ transplant patients may be monitored and diagnosed according to the claimed methods. Biological fluids, such as blood, (serum) or urine, are analyzed immunologically using a particularly adapted ELISA which are then compared to an FSC control concentration to identify elevated FSC values. Animals with test FSC above FSC control concentrations are diagnosed as having an ongoing organ rejection episode. The detection of congenital renal dysfunction in utero is also provided according to the present invention through the measurement of FSC in the amniotic fluid.
    Type: Grant
    Filed: December 28, 1993
    Date of Patent: January 16, 1996
    Assignee: The Board of Regents, The University of Texas System
    Inventors: Randall M. Goldblum, Srinivasan Rajaraman
  • Patent number: 5340721
    Abstract: Methods of monitoring and detecting the early onset of organ injury incident rejection of an organ rejection in an animal are disclosed. The described methods are capable of distinguishing organ rejection injury from other organ tissue damage in the animal. Free secretory component levels in an animal biological fluid (e.g., bile, urine, blood, amniotic fluid) may be used to identify organ rejection in an animal. Multiple and single organ transplant patients may be monitored and diagnosed according to the claimed methods. Biological fluids, such as blood, (serum) or urine, are analyzed immunologically using a particularly adapted ELISA which are then compared to an FSC control concentration to identify elevated FSC values. Animals with test FSC above FSC control concentrations are diagnosed as having an ongoing organ rejection episode. The detection of congenital renal dysfunction in utero is also provided according to the present invention through the measurement of FSC in the amniotic fluid.
    Type: Grant
    Filed: July 26, 1991
    Date of Patent: August 23, 1994
    Assignee: Board of Regents, The University of Texas System
    Inventors: Randall M. Goldblum, Srinivasan Rajaraman